In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

• Mechanisms of acquired resistance to TRK inhibitor therapy
• Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
• Safety profiles of first- vs second-generation TRK inhibitors

Presenters:

George D. Demetri, MD
Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director, Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD
Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Link to full program, including downloadable slides:
https://bit.ly/2YFIPfr

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.